Agenda – Pain Management Summit

  • Day One
  • Day Two

Day One

 Tuesday, November 19

9:00AM – 9:15AM

INTRODUCTION FROM CHAIRPERSON
Joe Stauffer, Chief Medical Officer, INHERIS BIOPHARMA

9:15AM – 10:00AM

KEYNOTE: NOVEL ANALGESICS: WHAT’S NEW IN PHASES 1-3
Joseph V. Pergolizzi, M.D., Senior Partner, NAPLES ANESTHESIA AND PAIN ASSOCIATES

10:00AM – 10:45AM

CATEGORY 1 TESTING: ABUSE-DETERRENT FORMULATIONS
Sebastian Schwier, Ph.D., Director, Transfer and Integration Management, GRUNENTHAL

10:45AM – 11:15AM

NETWORKING BREAK

11:15AM – 12:00PM

GROUNDBREAKING INNOVATION FOR CHRONIC PAIN
Joe Stauffer, Chief Medical Officer, INHERIS BIOPHARMA

12:00PM – 1:00PM

LUNCH BREAK

1:00PM – 1:45PM

CBD AND THC: WHAT HEALTHCARE PROFESSIONALS NEED TO KNOW
Debra R. Wilson, Ph.D., Contributing Faculty, WALDEN UNIVERSITY AND AUSTIN PEAY STATE UNIVERSITY

1:45PM – 2:30PM

A BREAKDOWN OF CBD: PAIN TREATMENT, COMBINATION THERAPEUTICS, MYTHS, AND REGULATIONS
Alex Wasyl, Chief Executive Officer, NEXIEN BIOPHARMA

2:30PM – 3:00PM

NETWORKING BREAK

3:00PM – 3:45PM

THE EMERGENCE OF CANNABINOIDS AS ANALGESICS AND THE INADEQUACY OF RESEARCH DATA
Caroline Arout, Ph.D., Research Scientist and Assistant Professor of Clinical Neurobiology, NEW YORK STATE PSYCHIATRIC INSTITUTE AT COLUMBIA UNIVERSITY IRVING MEDICAL CENTER

3:45PM – 4:30PM

VOICE OF THE PATIENT: CANNABIS USE FOR COMPLEX REGIONAL PAIN SYNDROME, TYPE 2 MANAGEMENT
Ashley Elsner, Chief Executive Officer and Founder, ARTERY INC.

4:30PM – 5:15PM

A NOVEL NON-OPIOID THERAPEUTIC FOR THE TREATMENT OF POST-SURGICAL PAIN AND PAINFUL DIABETIC NEUROPATHY
Scott L. Dax, Ph.D., Chief Scientific Officer, CERSCI THERAPEUTICS


Day Two

 Wednesday, November 20

8:00AM – 9:00AM

CONTINENTAL BREAKFAST

9:00AM – 9:15AM

INTRODUCTION FROM CHAIRPERSON
Steven D. Passik, Ph.D., Vice President, Scientific Affairs, Education, and Policy, COLLEGIUM PHARMACEUTICALS

9:15AM – 10:00AM

KEYNOTE: EXPLORE THE NEXT GENERATION OF ANALGESICS USING BASIC SCIENCE
Robert Raffa, Ph.D., Chief Scientific Officer, NEUMENTUM, INC.

10:00AM – 10:45AM

DESMETRAMADOL: ACTIVE METABOLITE OF TRAMADOL
John A. Zebala, M.D., Ph.D., Chief Executive Officer and President, SYNTRIX PHARMACEUTICALS

10:45AM – 11:15AM

NETWORKING BREAK

11:15AM – 12:00PM

FUNDING AN EARLY-STAGE PAIN COMPANY
Tim Peara, President and Finance Director, BRIDGE THERAPEUTICS

12:00PM – 12:45PM

DEBUNKING MYTHS: MISINTERPRETATIONS SURROUNDING OPIOID PRESCRIBING TRENDS AND THE PSEUDOSCIENCE OF MORPHINE EQUIVALENT DOSES
Jeffrey Fudin, Pharm.D., Chief Executive Officer and Chief Medical Officer, REMITIGATE, LLC.

12:45PM – 1:45PM

LUNCH BREAK

1:45PM – 2:30PM

A MODEST PROPOSAL: ADDRESSING THE COMPONENTS AND COMPLEXITIES OF COORDINATED CARE
Steven D. Passik, Ph.D., Vice President, Scientific Affairs, Education, and Policy, COLLEGIUM PHARMACEUTICALS

2:30PM – 3:15PM

REVISIT THE CDC GUIDELINES — LOOK WHERE WE ARE NOW!
Gary W. Jay, M.D., FAAPM, Clinical Professor, Department of Neurology, UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL

3:15PM – 4:00PM

POLICIES TO SUPPORT THE DEVELOPMENT OF NOVEL AND SAFER PAIN THERAPIES
Danielle Friend, Ph.D., Director, Science and Regulatory Affairs, BIOTECHNOLOGY INNOVATION ORGANIZATION